1. Association Between Preoperative Hypoalbuminemia and Risk of Perioperative Allogeneic Red Blood Cell in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Single-center Retrospective Cohort Study
- Author
-
LIU Wei, XU Xiaohan, and YU Xuerong
- Subjects
hypoproteinemia ,ovarian cancer ,tumor cell reduction ,allogeneic red blood cell infusion ,Medicine - Abstract
ObjectiveTo analyze the correlation between preoperative hypoproteinemia and the risk of perioperative allogeneic erythrocyte transfusion in ovarian cancer patients undergoing cytoreductive surgery.MethodsOvarian cancer patients who underwent cytoreductive surgery at Peking Union Medical College Hospital from January 2014 to December 2018 were retrospectively included. Clinical data such as the patients' general information, preoperative plasma albumin, American Society of Anesthesiologists(ASA) classification, intraoperative bleeding volume, operation time, perioperative (intraoperative and within 3 d postoperatively)allogeneic red blood cell transfusion were collected, and the correlation between preoperative hypoproteinemia (plasma albumin < 35 g/L) and the risk of allogeneic red blood cell infusion was analyzed by using multivariate Logistic regression.ResultsA total of 1001 ovarian cancer patients who met the inclusion and exclusion criteria were enrolled, of which 64 (6.4%) had preoperative hypoproteinemia and 481(48.1%) received perioperative allogeneic red blood cell transfusion. The rate of perioperative allogeneic red blood cell transfusion was higher in the patients with hypoproteinemia than in those without hypoproteinemia [84.4% (54/64) vs. 45.6% (427/937), P < 0.001]. Multivariate Logistic regression analysis corrected for confounders such as ASA classification, intraoperative bleeding volume, and operative time found that preoperative hypoproteinemia was significantly associated with the risk of perioperative allogeneic red blood cell transfusion (OR=5.68, 95% CI: 2.56-13.57, P < 0.001).ConclusionPreoperative hypoalbuminemia could be associated with the increased risk of perioperative transfusion in patients undergoing cytoreductive surgery for ovarian cancer.
- Published
- 2024
- Full Text
- View/download PDF